rss
Br J Ophthalmol 2004;88:1422-1424 doi:10.1136/bjo.2004.048033
  • Clinical science
    • Scientific reports

Epiphora as a side effect of topical mitomycin C

  1. E Dafgård Kopp,
  2. S Seregard
  1. St Erik’s Eye Hospital, Karolinska Institutet, Polhemsgatan 50, S-112 82 Stockholm, Sweden
  1. Correspondence to: Eva Dafgård Kopp St Erik’s Eye Hospital, Karolinska Institutet, Polhemsgatan 50, S-112 82 Stockholm, Sweden; eva.dafgardsankterik.se
  • Accepted 16 May 2004

Abstract

Aim: To report symptoms and findings of lacrimal duct malfunction after topical mitomycin C (MMC) for conjunctival neoplasia.

Methods: 14 consecutive patients treated with 1–6 cycles of topical 0.04% MMC four times daily for periods of 2 weeks were interviewed about symptoms of lacrimal duct malfunction. Patients who complained of tearing had examination of the puncta and canaliculi including probing and lacrimal duct irrigation.

Results: Nine patients complained of epiphora after topical MMC. Three of these patients had normal puncta and canaliculi, patent to irrigation. In these patients epiphora ceased spontaneously after probing and irrigation. The additional six patients had stenosis of the punctum (n = 3), the common canaliculus (n = 1), both puncta and both canaliculi (n = 1) and complete occlusion of the lower canaliculus (n = 1).

Conclusion: Obstruction of the puncta or canaliculi is not an infrequent event after topical 0.04% MMC.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.